These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 11505947)

  • 21. Ongoing progress in research on drug exposure and adverse events.
    Knottnerus JA; Tugwell P
    J Clin Epidemiol; 2012 Oct; 65(10):1029-30. PubMed ID: 22910535
    [No Abstract]   [Full Text] [Related]  

  • 22. European commission consultation on pharmacovigilance.
    Waller P; Beard K; Egberts T; Evans S; Hallas J; Hasford J; Laporte JR; Moore N; Shakir S; Sturkenboom M
    Pharmacoepidemiol Drug Saf; 2008 Feb; 17(2):108-9. PubMed ID: 18058839
    [No Abstract]   [Full Text] [Related]  

  • 23. First, gather the data.
    Hunter D
    N Engl J Med; 2006 Jan; 354(4):329-31. PubMed ID: 16436764
    [No Abstract]   [Full Text] [Related]  

  • 24. Variability in patterns of drug usage.
    Leufkens HG; Urquhart J
    J Pharm Pharmacol; 1994 May; 46 Suppl 1():433-7. PubMed ID: 8064562
    [No Abstract]   [Full Text] [Related]  

  • 25. Pharmaceutical expenditure compared across countries.
    van Mosseveld C
    Can J Clin Pharmacol; 2005; 12(3):e269-75. PubMed ID: 16373959
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Active drug safety surveillance: a tool to improve public health.
    Platt R; Madre L; Reynolds R; Tilson H
    Pharmacoepidemiol Drug Saf; 2008 Dec; 17(12):1175-82. PubMed ID: 18823068
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Signal detection in pharmacovigilance: empirical evaluation of data mining tools.
    Chan KA; Hauben M
    Pharmacoepidemiol Drug Saf; 2005 Sep; 14(9):597-9. PubMed ID: 16134080
    [No Abstract]   [Full Text] [Related]  

  • 28. [Sex differences in pharmacology].
    Brøsen K
    Ugeskr Laeger; 2007 Jun; 169(25):2408-11. PubMed ID: 17594829
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Brief introduction to pharmacoepidemiology].
    Geng G; Edlavitch SA
    Zhonghua Liu Xing Bing Xue Za Zhi; 1990 Dec; 11(6):368-71. PubMed ID: 2276190
    [No Abstract]   [Full Text] [Related]  

  • 30. Study of drug utilization among students at Lisbon University in Portugal.
    Cabrita J; Ferreira HS; Iglésias P; Baptista TM; Rocha E; da Silva LA; Miguel PJ
    Pharmacoepidemiol Drug Saf; 2002 Jun; 11(4):333-4. PubMed ID: 12138602
    [No Abstract]   [Full Text] [Related]  

  • 31. Pharmacoepidemiology and rheumatic disorders.
    Chan KA; Hernandez-Diaz S
    Rheum Dis Clin North Am; 2004 Nov; 30(4):835-50, vii. PubMed ID: 15488696
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influence of drugs and comorbidity on serum potassium in 15 000 consecutive hospital admissions.
    Henz S; Maeder MT; Huber S; Schmid M; Loher M; Fehr T
    Nephrol Dial Transplant; 2008 Dec; 23(12):3939-45. PubMed ID: 18614817
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [More transparency in drug safety].
    Saussele T
    Med Monatsschr Pharm; 2009 Sep; 32(9):325. PubMed ID: 19795694
    [No Abstract]   [Full Text] [Related]  

  • 34. Risk assessment of drugs, biologics and therapeutic devices: present and future issues.
    Centers for Education and Research on Therapeutics Risk Assessment Workshop
    Pharmacoepidemiol Drug Saf; 2003 Dec; 12(8):653-62. PubMed ID: 14762981
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Drug safety. Notes about surveillance].
    Moreno Alvarez PJ; Madurga Sanz M
    Farm Hosp; 2004; 28(3):225-8. PubMed ID: 15222877
    [No Abstract]   [Full Text] [Related]  

  • 36. Using pharmacoepidemiology to inform drug coverage policy: initial lessons from a two-province collaborative.
    Paterson JM; Laupacis A; Bassett K; Anderson GM;
    Health Aff (Millwood); 2006; 25(5):1436-43. PubMed ID: 16966744
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacoepidemiology and drug safety.
    Pharmacoepidemiol Drug Saf; 2003; 12(7):617-32. PubMed ID: 14558186
    [No Abstract]   [Full Text] [Related]  

  • 38. A multiattribute model for evaluating the benefit-risk profiles of treatment alternatives.
    Felli JC; Noel RA; Cavazzoni PA
    Med Decis Making; 2009; 29(1):104-15. PubMed ID: 18812582
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacoepidemiology and drug safety.
    Pharmacoepidemiol Drug Saf; 2003 Mar; 12(2):161-76. PubMed ID: 12642981
    [No Abstract]   [Full Text] [Related]  

  • 40. Pharmacoepidemiology and drug safety.
    Pharmacoepidemiol Drug Saf; 2004 Jan; 13(1):49-64. PubMed ID: 14971123
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.